Literature DB >> 31513803

Somatic Mosaic NLRP3 Mutations and Inflammasome Activation in Late-Onset Chronic Urticaria.

Eman Assrawi1, Camille Louvrier2, Clémence Lepelletier3, Sophie Georgin-Lavialle4, Jean-David Bouaziz3, Fawaz Awad5, Florence Moinet6, Philippe Moguelet7, Marie Dominique Vignon-Pennamen8, William Piterboth9, Claire Jumeau1, Laetitia Cobret1, Elma El Khouri1, Bruno Copin9, Philippe Duquesnoy1, Marie Legendre2, Gilles Grateau4, Sonia A Karabina1, Serge Amselem10, Irina Giurgea11.   

Abstract

Chronic urticaria is a common skin disorder with heterogeneous causes. In the absence of physical triggers, chronic urticarial rash is called idiopathic or spontaneous. The objective of this study was to identify the molecular and cellular bases of a disease condition displayed by two unrelated patients aged over 60 years who presented for two decades with a chronic urticaria resistant to standard therapy that occurred in the context of systemic inflammation not triggered by cold. In both patients, a targeted sequencing approach using a next generation technology identified somatic mosaic mutations in NLRP3, a gene encoding a key inflammasome component. The study of several of both patients' cell types showed that, despite the late onset of the disease, NLRP3 mutations were not found to be restricted to myelomonocytic cells. Rather, the data obtained strongly suggested that the mutational event occurred very early, during embryonic development. As shown by functional studies, the identified mutations-an in-frame deletion and a recurrent NLRP3 missense mutation-have a gain-of-function effect on NLRP3-inflammasome activation. Consistently, a complete remission was obtained in both patients with anti-IL-1 receptor antagonists. This study unveils that in late-onset chronic urticaria, the search for autoinflammatory markers and somatic mosaic NLRP3 mutations may have important diagnostic and therapeutic consequences.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31513803     DOI: 10.1016/j.jid.2019.06.153

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

Review 1.  Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases.

Authors:  Ivona Aksentijevich; Oskar Schnappauf
Journal:  Nat Rev Rheumatol       Date:  2021-05-25       Impact factor: 20.543

Review 2.  Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond.

Authors:  Keith A Sikora; Kristina V Wells; Ertugrul Cagri Bolek; Adrianna I Jones; Peter C Grayson
Journal:  Rheumatology (Oxford)       Date:  2022-08-03       Impact factor: 7.046

Review 3.  Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

Authors:  Ana M Giménez-Arnau; Andaç Salman
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

4.  Neutrophilic Urticaria with Systemic Inflammation Associated with Immunoglobulin A Myeloma.

Authors:  Héloïse Paugoy; Anne Saussine; Laure Frumholtz; Maxime Battistella; Marie Jachiet; Jacqueline Rivet; Clémence Lepelletier; Lucie Duverger; Martine Bagot; Alexis Talbot; Bertrand Arnulf; Jean-David Bouaziz
Journal:  Acta Derm Venereol       Date:  2021-04-27       Impact factor: 3.875

5.  Computational Modeling of NLRP3 Identifies Enhanced ATP Binding and Multimerization in Cryopyrin-Associated Periodic Syndromes.

Authors:  Jenny Mae Samson; Dinoop Ravindran Menon; Prasanna K Vaddi; Nazanin Kalani Williams; Joanne Domenico; Zili Zhai; Donald S Backos; Mayumi Fujita
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

6.  Yanghe Pingchuan Granules Alleviate Airway Inflammation in Bronchial Asthma and Inhibit Pyroptosis by Blocking the TLR4/NF-κB/NRLP3 Signaling Pathway.

Authors:  Lingyu Pan; Yan Chen; Yeke Jiang; Yehong Sun; Yanquan Han; Yongzhong Wang
Journal:  Mediators Inflamm       Date:  2022-08-31       Impact factor: 4.529

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.